Van ECK Associates Corp trimmed its position in shares of Valeant Pharmaceuticals International, Inc. (NYSE:VRX) (TSE:VRX) by 16.6% during the second quarter, according to its most recent Form 13F filing with the SEC. The firm owned 414,646 shares of the specialty pharmaceutical company’s stock after selling 82,626 shares during the period. Van ECK Associates Corp owned about 0.12% of Valeant Pharmaceuticals International worth $7,173,000 at the end of the most recent reporting period.

Several other hedge funds have also recently added to or reduced their stakes in the stock. ValueAct Holdings L.P. increased its stake in shares of Valeant Pharmaceuticals International by 20.0% during the first quarter. ValueAct Holdings L.P. now owns 17,997,224 shares of the specialty pharmaceutical company’s stock worth $198,509,000 after buying an additional 3,002,963 shares during the period. Vanguard Group Inc. increased its stake in shares of Valeant Pharmaceuticals International by 9.8% during the first quarter. Vanguard Group Inc. now owns 6,980,074 shares of the specialty pharmaceutical company’s stock worth $76,990,000 after buying an additional 621,618 shares during the period. Bank of Montreal Can increased its stake in shares of Valeant Pharmaceuticals International by 9.8% during the second quarter. Bank of Montreal Can now owns 6,330,670 shares of the specialty pharmaceutical company’s stock worth $109,521,000 after buying an additional 564,215 shares during the period. OppenheimerFunds Inc. increased its stake in shares of Valeant Pharmaceuticals International by 17.1% during the first quarter. OppenheimerFunds Inc. now owns 4,489,169 shares of the specialty pharmaceutical company’s stock worth $49,516,000 after buying an additional 656,116 shares during the period. Finally, CIBC World Markets Inc. increased its stake in shares of Valeant Pharmaceuticals International by 2.3% during the second quarter. CIBC World Markets Inc. now owns 3,741,413 shares of the specialty pharmaceutical company’s stock worth $64,726,000 after buying an additional 83,592 shares during the period. Hedge funds and other institutional investors own 50.47% of the company’s stock.

WARNING: This piece was first published by Daily Political and is the property of of Daily Political. If you are reading this piece on another domain, it was copied illegally and reposted in violation of United States & international copyright and trademark laws. The legal version of this piece can be accessed at https://www.dailypolitical.com/2017/09/23/van-eck-associates-corp-sells-82626-shares-of-valeant-pharmaceuticals-international-inc-vrx.html.

Shares of Valeant Pharmaceuticals International, Inc. (NYSE:VRX) opened at 14.01 on Friday. Valeant Pharmaceuticals International, Inc. has a one year low of $8.31 and a one year high of $27.84. The company’s 50 day moving average price is $14.22 and its 200 day moving average price is $13.18. The firm’s market capitalization is $4.88 billion.

Valeant Pharmaceuticals International (NYSE:VRX) (TSE:VRX) last issued its quarterly earnings data on Tuesday, August 8th. The specialty pharmaceutical company reported $1.05 EPS for the quarter, topping the Zacks’ consensus estimate of $0.97 by $0.08. The firm had revenue of $2.23 billion during the quarter, compared to the consensus estimate of $2.23 billion. Valeant Pharmaceuticals International had a positive return on equity of 59.89% and a negative net margin of 12.40%. The firm’s revenue was down 7.7% on a year-over-year basis. During the same period in the prior year, the business earned ($0.88) EPS. On average, analysts expect that Valeant Pharmaceuticals International, Inc. will post $3.89 EPS for the current fiscal year.

In related news, Director Schutter Richard U. De acquired 10,000 shares of the stock in a transaction that occurred on Monday, August 21st. The stock was purchased at an average cost of $14.33 per share, for a total transaction of $143,300.00. Following the purchase, the director now directly owns 77,479 shares in the company, valued at $1,110,274.07. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. 5.87% of the stock is owned by corporate insiders.

VRX has been the topic of a number of recent research reports. Wells Fargo & Company dropped coverage on shares of Valeant Pharmaceuticals International in a research note on Sunday, July 30th. BidaskClub lowered shares of Valeant Pharmaceuticals International from a “hold” rating to a “sell” rating in a research note on Friday, June 16th. Vetr lowered shares of Valeant Pharmaceuticals International from a “strong-buy” rating to a “sell” rating and set a $13.30 target price on the stock. in a research note on Thursday, August 24th. Stifel Nicolaus restated a “buy” rating and set a $35.00 target price on shares of Valeant Pharmaceuticals International in a research note on Friday, June 30th. Finally, ValuEngine lowered shares of Valeant Pharmaceuticals International from a “buy” rating to a “hold” rating in a research note on Friday, September 1st. Five investment analysts have rated the stock with a sell rating, fourteen have assigned a hold rating and four have given a buy rating to the company’s stock. Valeant Pharmaceuticals International currently has a consensus rating of “Hold” and an average target price of $17.62.

Valeant Pharmaceuticals International Profile

Valeant Pharmaceuticals International, Inc is a pharmaceutical and medical device company. The Company is engaged in developing and marketing a range of branded, generic and branded generic pharmaceuticals, over-the-counter (OTC) products, and medical devices (contact lenses, intraocular lenses, ophthalmic surgical equipment, and aesthetics devices).

Want to see what other hedge funds are holding VRX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Valeant Pharmaceuticals International, Inc. (NYSE:VRX) (TSE:VRX).

Institutional Ownership by Quarter for Valeant Pharmaceuticals International (NYSE:VRX)

Receive News & Ratings for Valeant Pharmaceuticals International Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Valeant Pharmaceuticals International Inc. and related companies with MarketBeat.com's FREE daily email newsletter.